Dose Formulation Analysis is an essential step in regulated nonclinical studies. Robust analytical methods, rapid turnaround, and efficient communication helps ensure the dose form results for your GLP studies are delivered on time. At KCAS Bio, our scientific expertise allows us to develop methods that achieve…

In episode 84 of “The Weekly Bioanalysis”, our special guest, Bryan Parmentier, joins Dom and John to discuss his background and current role at KCAS Bio, offering insights into the field of small molecule method development. He delves into the typical challenges encountered when working with LC-MS analytes, and how…

Biomarker assay development is pivotal to clinical research and the success of a study, yet the journey from qualification to validation is often complex. In this blog, we discuss four must-know essentials to optimize your assay development process. 1. Understand the Context of Use: Qualification vs. Validation The FDA emphasizes…

As the bioanalytical market evolves at a rapid pace, KCAS Bio stands at the forefront, offering an innovative approach to challenges and opportunities alike. Drawing on the insights of our leadership team, we’ve compiled a global perspective on the state of the bioanalytical industry in 2024. Through thoughtful discussions with…

In this exciting 15th episode of The Conversational Flow podcast, titled “Fantastic Fluorophores and Where to Find Them,” hosts Brian Wile and Adam Cotty from KCAS Bio are joined by special guest Kelly Lundsten from FluoroFinder. Together, they dive into the fascinating world of spectral flow cytometry, exploring key questions such as…

Drawing on the insights of our leadership team, we’ve compiled a global perspective on the state of the bioanalytical industry in 2024. Through thoughtful discussions with our CEO, John Bucksath, and key team members Amy Mize, Mouhssin Oufir, and Brian Wile, KCAS Bio delivers a roadmap…

Drawing on the insights of our leadership team, we’ve compiled a global perspective on the state of the bioanalytical industry in 2024. Through thoughtful discussions with our CEO, John Bucksath, and key team members Amy Mize, Mouhssin Oufir, and Brian Wile, KCAS Bio delivers a roadmap…

Drawing on the insights of our leadership team, we’ve compiled a global perspective on the state of the bioanalytical industry in 2024. Through thoughtful discussions with our CEO, John Bucksath, and key team members Amy Mize, Mouhssin Oufir, and Brian Wile, KCAS Bio delivers a roadmap…

Drawing on the insights of our leadership team, we’ve compiled a global perspective on the state of the bioanalytical industry in 2024. Through thoughtful discussions with our CEO, John Bucksath, and key team members Amy Mize, Mouhssin Oufir, and Brian Wile, KCAS Bio delivers a roadmap…

KCAS Bio is excited to sponsor the upcoming Pharmaceutical & BioScience Society (PBSS) workshop “Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical Design and Intellectual Property,” on December 10th from 8:45am – 5:30pm PST in San Diego, California at the Hyatt Regency – La Jolla. Showcasing…

The 2024 tradeshow and conference season is finally coming to a close for the pharmaceutical and biotech industry, and our road-weary traveling hosts, Dom and John have returned from their final event, the 2024 European Bioanalysis Forum (EBF) Open Symposium in Barcelona, Spain. EBF was founded in 2006 at the…

This infographic explores the key trends in flow cytometry, software and instrumentation based on results from a recent Spotlight survey. It highlights the top challenges for biomarker analysis using flow cytometry, including lack of standardized control materials, sourcing a suitable laboratory and uncertain regulatory expectation, as well as what the…